Symbols / AMIX $0.39 -1.14% Autonomix Medical, Inc.
AMIX Chart
About
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 4.45M |
| Enterprise Value | -5.43M | Income | -17.24M | Sales | — |
| Book/sh | 0.75 | Cash/sh | 0.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.05 | PEG | — |
| P/S | — | P/B | 0.52 | P/C | — |
| EV/EBITDA | 0.31 | EV/Sales | — | Quick Ratio | 6.02 |
| Current Ratio | 6.18 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.15 | EPS next Y | -7.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-11 17:00 | ROA | -98.98% |
| ROE | -188.75% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.41M |
| Shs Float | 11.06M | Short Float | 1.78% | Short Ratio | 1.16 |
| Short Interest | — | 52W High | 2.82 | 52W Low | 0.34 |
| Beta | -2.46 | Avg Volume | 975.97K | Volume | 112.82K |
| Target Price | $2.00 | Recom | None | Prev Close | $0.39 |
| Price | $0.39 | Change | -1.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.00
Mean price target
2. Current target
$0.39
Latest analyst target
3. DCF / Fair value
$-9.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.39
Low
$2.00
High
$2.00
Mean
$2.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Maxim Group | Buy → Buy | $2 |
| 2025-04-29 | init | Maxim Group | — → Buy | $5 |
| 2024-09-03 | init | Ladenburg Thalmann | — → Buy | $1 |
- New nerve-targeting tech lands CRT 2026 Best Innovation stage - Stock Titan hu, 05 Mar 2026 08
- AMIX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Sat, 04 Apr 2026 14
- AMIX Stock Price and Chart — NASDAQ:AMIX - TradingView ue, 29 Jul 2025 07
- Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why - Yahoo Finance hu, 31 Jul 2025 07
- Autonomix Medical receives Nasdaq notice for minimum bid price deficiency - Investing.com Fri, 16 Jan 2026 08
- Will Autonomix Medical Inc. Stock Soar? - StocksToTrade Mon, 17 Nov 2025 08
- AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech - Nasdaq hu, 22 May 2025 07
- Autonomix Medical to Present at LSI USA ’26 - GlobeNewswire Wed, 11 Mar 2026 07
- Should I buy Autonomix Medical, Inc. (AMIX) - Zacks Investment Research hu, 22 May 2025 07
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 03 Feb 2026 08
- New procedure helps ease severe pancreatic cancer pain fast - Stock Titan Fri, 09 Jan 2026 08
- Autonomix Medical Selected for Best Innovation Competition at CRT 2026 - GlobeNewswire hu, 05 Mar 2026 08
- Medtech summit talk: Autonomix CEO on stage at LSI USA ’26 - Stock Titan Wed, 11 Mar 2026 07
- Autonomix Medical stock soars after pain relief data in pancreatic cancer By Investing.com - Investing.com South Africa Fri, 09 Jan 2026 08
- 12 Health Care Stocks Moving In Friday's After-Market Session - Firefly Neuroscience (NASDAQ:AIFF), Auton - Benzinga Fri, 20 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
11.59
+55.04%
|
7.47
+275.58%
|
1.99
|
| Research And Development |
|
4.72
+112.36%
|
2.23
+198.66%
|
0.74
|
| Selling General And Administration |
|
6.86
+30.75%
|
5.25
+321.61%
|
1.25
|
| General And Administrative Expense |
|
6.86
+30.75%
|
5.25
+321.61%
|
1.25
|
| Other Gand A |
|
6.86
+30.75%
|
5.25
+321.61%
|
1.25
|
| Total Expenses |
|
11.59
+55.04%
|
7.47
+275.58%
|
1.99
|
| Operating Income |
|
-11.59
-55.04%
|
-7.47
-275.58%
|
-1.99
|
| Total Operating Income As Reported |
|
-11.59
+3.67%
|
-12.03
-504.52%
|
-1.99
|
| EBITDA |
|
-11.05
+27.61%
|
-15.27
-667.14%
|
-1.99
|
| Normalized EBITDA |
|
-11.05
-52.09%
|
-7.27
-265.13%
|
-1.99
|
| Reconciled Depreciation |
|
0.18
+125.93%
|
0.08
|
0.00
|
| EBIT |
|
-11.23
+26.80%
|
-15.35
-671.21%
|
-1.99
|
| Total Unusual Items |
|
—
|
-8.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
-8.00
|
—
|
| Net Income |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Pretax Income |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Net Non Operating Interest Income Expense |
|
0.18
+270.83%
|
0.05
|
0.00
|
| Interest Expense Non Operating |
|
0.18
+122.78%
|
0.08
|
0.00
|
| Net Interest Income |
|
0.18
+270.83%
|
0.05
|
0.00
|
| Interest Expense |
|
0.18
+122.78%
|
0.08
|
0.00
|
| Interest Income Non Operating |
|
0.35
+178.74%
|
0.13
|
0.00
|
| Interest Income |
|
0.35
+178.74%
|
0.13
|
0.00
|
| Other Income Expense |
|
—
|
-8.00
|
—
|
| Gain On Sale Of Security |
|
—
|
-8.00
|
—
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Net Income From Continuing And Discontinued Operation |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Net Income Continuous Operations |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Normalized Income |
|
-11.41
-53.65%
|
-7.43
-273.17%
|
-1.99
|
| Net Income Common Stockholders |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Diluted EPS |
|
-6.46
+56.41%
|
-14.82
-686.35%
|
-1.88
|
| Basic EPS |
|
-6.46
+56.41%
|
-14.82
-686.35%
|
-1.88
|
| Basic Average Shares |
|
1.77
+69.73%
|
1.04
-1.44%
|
1.06
|
| Diluted Average Shares |
|
1.77
+69.73%
|
1.04
-1.44%
|
1.06
|
| Diluted NI Availto Com Stockholders |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Assets |
|
9.81
+4.24%
|
9.41
+987.51%
|
0.86
|
| Current Assets |
|
9.61
+2.32%
|
9.39
+985.66%
|
0.86
|
| Cash Cash Equivalents And Short Term Investments |
|
9.14
+6.13%
|
8.61
+895.14%
|
0.86
|
| Cash And Cash Equivalents |
|
9.14
+6.13%
|
8.61
+895.14%
|
0.86
|
| Cash Financial |
|
—
|
8.61
+895.14%
|
0.86
|
| Other Current Assets |
|
0.47
-39.59%
|
0.78
|
—
|
| Total Non Current Assets |
|
0.20
+1131.25%
|
0.02
|
0.00
|
| Net PPE |
|
0.02
+31.25%
|
0.02
|
0.00
|
| Non Current Deferred Assets |
|
0.18
|
0.00
|
—
|
| Total Liabilities Net Minority Interest |
|
1.71
-4.05%
|
1.78
+704.98%
|
0.22
|
| Current Liabilities |
|
1.71
+119.69%
|
0.78
+251.58%
|
0.22
|
| Payables And Accrued Expenses |
|
1.71
+119.69%
|
0.78
+251.58%
|
0.22
|
| Payables |
|
0.68
+37.40%
|
0.49
+184.39%
|
0.17
|
| Accounts Payable |
|
0.68
+37.40%
|
0.49
+184.39%
|
0.17
|
| Current Accrued Expenses |
|
1.03
+261.75%
|
0.28
+493.75%
|
0.05
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
1.00
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
1.00
|
—
|
| Long Term Debt |
|
—
|
1.00
|
—
|
| Stockholders Equity |
|
8.10
+6.17%
|
7.63
+1084.47%
|
0.64
|
| Common Stock Equity |
|
8.10
+6.17%
|
7.63
+1084.47%
|
0.64
|
| Capital Stock |
|
0.00
+100.00%
|
0.00
-91.67%
|
0.01
|
| Common Stock |
|
0.00
+100.00%
|
0.00
-91.67%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
2.50
+164.99%
|
0.94
-10.76%
|
1.06
|
| Ordinary Shares Number |
|
2.50
+164.99%
|
0.94
-10.76%
|
1.06
|
| Additional Paid In Capital |
|
58.48
+25.50%
|
46.60
+92.74%
|
24.18
|
| Retained Earnings |
|
-50.38
-29.28%
|
-38.97
-65.52%
|
-23.54
|
| Total Equity Gross Minority Interest |
|
8.10
+6.17%
|
7.63
+1084.47%
|
0.64
|
| Total Capitalization |
|
8.10
-6.15%
|
8.63
+1240.06%
|
0.64
|
| Working Capital |
|
7.90
-8.27%
|
8.61
+1237.58%
|
0.64
|
| Invested Capital |
|
8.10
-6.15%
|
8.63
+1240.06%
|
0.64
|
| Total Debt |
|
—
|
1.00
|
—
|
| Net Tangible Assets |
|
8.10
+6.17%
|
7.63
+1084.47%
|
0.64
|
| Tangible Book Value |
|
8.10
+6.17%
|
7.63
+1084.47%
|
0.64
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-8.26
-24.22%
|
-6.65
-258.58%
|
-1.85
|
| Cash Flow From Continuing Operating Activities |
|
-8.26
-24.22%
|
-6.65
-258.58%
|
-1.85
|
| Net Income From Continuing Operations |
|
-11.41
+26.03%
|
-15.43
-675.18%
|
-1.99
|
| Depreciation Amortization Depletion |
|
0.18
+125.93%
|
0.08
|
0.00
|
| Depreciation And Amortization |
|
0.18
+125.93%
|
0.08
|
0.00
|
| Other Non Cash Items |
|
0.10
|
—
|
—
|
| Stock Based Compensation |
|
1.63
+163.43%
|
0.62
|
0.00
|
| Operating Gains Losses |
|
—
|
8.00
|
—
|
| Gain Loss On Investment Securities |
|
—
|
8.00
|
—
|
| Change In Working Capital |
|
1.24
+1469.62%
|
0.08
-41.91%
|
0.14
|
| Change In Payables And Accrued Expense |
|
0.93
+66.97%
|
0.56
+338.58%
|
0.13
|
| Change In Accrued Expense |
|
0.75
+214.77%
|
0.24
+415.22%
|
0.05
|
| Change In Payable |
|
0.18
-42.50%
|
0.32
+295.06%
|
0.08
|
| Change In Account Payable |
|
0.18
-42.50%
|
0.32
+295.06%
|
0.08
|
| Change In Other Current Assets |
|
0.31
+164.85%
|
-0.48
-5411.11%
|
0.01
|
| Investing Cash Flow |
|
-0.01
+26.32%
|
-0.02
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
+26.32%
|
-0.02
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.01
+26.32%
|
-0.02
|
0.00
|
| Purchase Of PPE |
|
-0.01
+26.32%
|
-0.02
|
0.00
|
| Capital Expenditure |
|
-0.01
+26.32%
|
-0.02
|
—
|
| Financing Cash Flow |
|
8.80
-38.93%
|
14.41
+2034.81%
|
0.68
|
| Cash Flow From Continuing Financing Activities |
|
8.80
-38.93%
|
14.41
+2034.81%
|
0.68
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
2.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
2.00
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
2.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
2.00
|
0.00
|
| Net Common Stock Issuance |
|
10.03
-26.84%
|
13.71
+1930.52%
|
0.68
|
| Proceeds From Stock Option Exercised |
|
0.00
|
0.00
|
—
|
| Net Other Financing Charges |
|
-1.23
+5.25%
|
-1.30
|
—
|
| Changes In Cash |
|
0.53
-93.18%
|
7.74
+756.74%
|
-1.18
|
| Beginning Cash Position |
|
8.61
+895.14%
|
0.86
-57.68%
|
2.04
|
| End Cash Position |
|
9.14
+6.13%
|
8.61
+895.14%
|
0.86
|
| Free Cash Flow |
|
-8.27
-24.07%
|
-6.67
-259.60%
|
-1.85
|
| Common Stock Issuance |
|
10.03
-26.84%
|
13.71
+1930.52%
|
0.68
|
| Issuance Of Capital Stock |
|
10.03
-26.84%
|
13.71
+1930.52%
|
0.68
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-02-11 View
- 8-K2026-01-16 View
- 8-K2026-01-09 View
- 8-K2025-11-19 View
- 10-Q2025-11-12 View
- 8-K2025-11-03 View
- 8-K2025-08-27 View
- 8-K2025-08-26 View
- 42025-08-13 View
- 42025-08-13 View
- 42025-08-13 View
- 42025-08-13 View
- 42025-08-13 View
- 10-Q2025-08-13 View
- 8-K2025-07-22 View
- 10-K2025-05-29 View
- 8-K2025-04-30 View
- 8-K2025-02-28 View
- 8-K2025-02-13 View
- 10-Q2025-02-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|